scispace - formally typeset
Open AccessJournal ArticleDOI

Non-Contraceptive Benefits of Oral Hormonal Contraceptives

Adolf E. Schindler
- 21 Dec 2012 - 
- Vol. 11, Iss: 1, pp 41-47
Reads0
Chats0
TLDR
Oral combined hormonal contraceptives (estrogen/ progestogen combination) are - besides being reliable forms of contraception - are cost-effective medications for many medical disorders in women and should be used in clinical practice.
Abstract
It is becoming evident that oral hormonal contraceptives-besides being well established contraceptives-seem to become important medications for many functional or organic disturbances. So far, clinical effectiveness has been shown for treatment as well as prevention of menstrual bleeding disorders and menstrual-related pain symptoms. Also this is true for premenstrual syndrome (PMS) and premenstrual disphoric disorder (PMDD). Particular oral contraceptives (OCs) containing anti-androgenic progestogens were shown to be effective medications for treatment of androgenisation symptoms (seborrhea, acne, hirsutism, alopecia). Through perfect suppression of the hypothalamic-pituitary-ovarian axis OCs have proven to be effective in elimination of persistent follicular cysts. Endometriosis/adenomyosis related pain symptoms are well handled similar to other drugs like Gonadotropine Releasing Hormone agonists but are less expensive, with less side effects, and possibility to be used for longer periods of time. This is also true for myoma. Pelvic inflammatory disease, rheumatoid arthritis, menstrual migraine, and onset of multiple sclerosis are prevented or delayed. Bone density is preserved and asthma symptoms improved. Endometrial hyperplasia and benign breast disease can be controlled. There is definitely a significant impact on risk reduction regarding endometrial, ovarian, and colon cancers. In conclusion, it needs to be recognized that oral combined hormonal contraceptives (estrogen/ progestogen combination) are - besides being reliable forms of contraception - are cost-effective medications for many medical disorders in women. Therefore, these contraceptives drugs are important for female and global health and should be used in clinical practice.

read more

Citations
More filters
Journal ArticleDOI

Hormonal contraceptives: pharmacology tailored to women's health

TL;DR: Progress in the provision of new oral contraceptives has improved the risk/benefit ratio, by increasing benefits and reducing risks.
Journal ArticleDOI

The menstrual cycle and the skin

TL;DR: The current understanding of the menstrual cycle, and its effect on the skin and cutaneous disorders is described.
Journal ArticleDOI

The Clinical Relevance of Progestogens in Hormonal Contraception: Present Status and Future Developments

Pedro-Antonio Regidor
- 02 Oct 2018 - 
TL;DR: Progestogens can be derived from testosterone, progesterone, and spironolactone that determine pharmacodynamic and pharmacokinetic differential effects that contribute to the tolerability and additional beneficial or therapeutic effects whether used in combined oral contraceptives COC or as progestogen only drugs enhancing the individual options for different patient profiles.
Journal ArticleDOI

Pediatric Ovarian Torsion

TL;DR: Investigation should include conservative management with laparoscopic adnexal detorsion and ovarian preservation even in the event of a necrotic-appearing ovary because studies persistently show follicular development and ovarian function after a short time period and no increased patient morbidity.
Journal ArticleDOI

Burden of menstrual symptoms in Japanese women - an analysis of medical care-seeking behavior from a survey-based study.

TL;DR: It is indicated that Japanese women who were suffering from menstrual symptoms could benefit from visiting a gynecologist for easing their symptoms, hence improving their daily life.
References
More filters
Journal ArticleDOI

Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls

TL;DR: It is suggested that oral contraceptives have already prevented some 200,000 ovarian cancers and 100,000 deaths from the disease, and that over the next few decades the number of cancers prevented will rise to at least 30,000 per year.
Journal ArticleDOI

Risk factors for uterine fibroids: reduced risk associated with oral contraceptives.

TL;DR: Investigation of risk factors for pathologically confirmed uterine leiomyomas (fibroids) in the Oxford Family Planning Association study showed that reproductive experiences were closely linked to development of fibroids, suggesting that the underlying risk factor is "unopposed" oestrogen.
Journal ArticleDOI

Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study

TL;DR: Oral contraception was not associated with an overall increased risk of cancer; indeed it may even produce a net public health gain; the balance of cancer risks and benefits may vary internationally, depending on patterns of oral contraception usage and the incidence of different cancers.
Journal ArticleDOI

The Reduction in Risk of Ovarian Cancer Associated with Oral-Contraceptive Use

TL;DR: A protective effect was seen in women who had used oral contraceptives for as little as three to six months, and it continued for 15 years after use ended, independent of the specific oral-contraceptive formulation and of the histologic type of epithelial ovarian cancer.
Related Papers (5)
Trending Questions (1)
How does treatment with a progestin oral contraceptive treat androgen excess and menstrual dysfunction?

Treatment with a progestin oral contraceptive can effectively treat androgen excess symptoms such as seborrhea, acne, hirsutism, and alopecia, as well as menstrual dysfunction.